sever
antiretrovir
drug
consid
use
treatment
diseas
caus
newli
identifi
coronaviru
proteas
inhibitor
consid
candid
therapi
inhibit
enzym
activ
envelop
glycoprotein
part
process
viral
entri
cell
use
lopinavirritonavir
lpvr
support
data
vitro
studi
anim
model
posit
clinic
outcom
lpvr
given
patient
infect
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
diseas
also
caus
coronavirus
antiretrovir
propos
base
virtual
screen
vitro
studi
sever
clinic
trial
plan
lopinavirritonavir
lpvr
includ
rapid
guidanc
issu
research
wuhan
univers
base
clinic
use
prior
epidem
sever
acut
respiratori
syndrom
sar
mer
coronaviru
cov
infect
systemat
review
summar
clinic
outcom
use
antiretrovir
drug
prevent
treatment
coronavirus
plan
clinic
trial
base
vitro
activ
molecular
dock
studi
report
use
prior
review
follow
drug
screen
lopinavirritonavir
emtricitabin
tenofovir
atazanavir
ritonavir
darunavir
nelfinavir
indinavir
saquinavir
lamivudin
zidovudin
search
strategi
provid
appendix
three
databas
medlin
via
pubm
embas
cochran
librari
screen
incept
march
studi
report
clinic
outcom
patient
sar
mer
treat
antiretrovir
studi
use
antiretrovir
prevent
infect
also
sought
databas
public
also
search
http
studi
design
report
clinic
outcom
data
includ
languag
restrict
clinicaitrialsgov
chictrorgcn
search
ongo
complet
trial
data
summar
per
studi
pool
due
limit
number
studi
report
outcom
diseas
review
conduct
singl
review
nf
data
extract
valid
second
review
ar
qualiti
certainti
evid
assess
use
grade
recommend
assess
develop
evalu
grade
approach
initi
screen
titl
two
random
control
trial
observ
studi
provid
clinic
outcom
data
use
antiretrovir
drug
treatment
studi
report
outcom
prevent
three
studi
exclud
one
caus
infect
unclear
one
origin
studi
retract
conduct
systemat
review
one
lamivudin
given
control
chronic
hepat
b
infect
use
could
link
sar
outcom
among
includ
studi
major
report
outcom
use
lpvr
treatment
two
two
studi
report
outcom
among
individu
combin
antiretrovir
drug
manag
hiv
characterist
includ
studi
patient
outcom
summar
tabl
two
observ
studi
one
case
report
among
patient
sar
report
outcom
patient
given
antiretrovir
studi
china
report
reduct
mortal
patient
receiv
lpvr
ci
compar
match
control
second
studi
china
report
none
patient
given
lpvr
die
compar
seven
patient
control
group
third
studi
also
china
case
report
man
recov
receiv
abacavir
efavirenz
tenofovir
lpvr
antiretrovir
therapi
patient
also
receiv
ribavirin
steroid
vari
dose
durat
six
observ
studi
includ
two
retrospect
observ
studi
four
case
report
one
greec
one
austria
two
saudi
arabia
two
republ
korea
provid
data
patient
diagnos
mer
death
among
patient
given
lpvr
togeth
intervent
includ
ribavirin
pegyl
interferon
one
random
control
studi
report
efficaci
safeti
lpvr
treat
hospit
adult
sever
trial
patient
receiv
lpvr
mg
twice
day
median
time
symptom
onset
random
day
patient
receiv
standard
care
day
lpvr
associ
statist
signific
differ
time
clinic
improv
day
mortal
numer
lower
lpvr
group
compar
control
group
differ
statist
signific
analysi
acceler
clinic
recoveri
reduc
mortal
observ
treat
within
day
symptom
onset
treat
later
almost
half
patient
lpvr
group
patient
control
group
patient
report
one
advers
event
complaint
includ
nausea
vomit
diarrhoea
common
lopinavirritonavir
group
second
random
trial
assess
patient
admit
hospit
mildmoder
compar
outcom
patient
given
lpvr
twice
day
patient
given
ardibol
patient
given
antivir
therapi
trial
lpvr
show
benefit
term
time
viral
clearanc
pcr
neg
progress
sever
diseas
trial
certainti
evid
low
due
risk
bia
investig
blind
intervent
imprecis
observ
studi
three
case
report
three
case
seri
six
observ
studi
report
outcom
patient
receiv
lpvr
nine
studi
china
one
singapor
two
republ
korea
among
patient
nine
studi
outcom
could
associ
receipt
lpvr
three
patient
die
one
studi
report
patient
receiv
lpvr
three
patient
die
howev
unclear
mani
patient
die
receiv
lpvr
lpvr
recommend
part
antiretrovir
therapi
among
peopl
live
hiv
receiv
lpvr
diarrhoea
nausea
vomit
commonli
report
side
effect
start
treatment
side
effect
report
four
five
individu
receiv
lpvr
treatment
singapor
one
individu
complet
treatment
cours
result
advers
event
certainti
evid
outcom
across
three
diseas
low
sampl
size
small
two
studi
provid
compar
outcom
one
use
histor
control
none
use
random
design
abl
assess
compar
effect
differ
intervent
time
durat
dose
treatment
vari
major
studi
patient
provid
intervent
may
contribut
report
outcom
grade
tabl
provid
appendix
three
studi
report
possibl
protect
effect
lpvr
coronaviru
infect
first
retrospect
observ
studi
china
note
patient
hospit
floor
sar
patient
contract
diseas
patient
differ
regimen
antiretrovir
therapi
none
receiv
lpvr
second
studi
south
korea
retrospect
enrol
health
care
worker
consid
high
risk
mer
infect
healthcar
worker
given
prophylaxi
pep
compris
ribavirin
lpvr
none
infect
compar
healthcar
worker
given
pep
becam
infect
third
studi
china
compar
characterist
individu
differ
antiretrovir
regimen
contract
infect
patient
infect
statist
signific
relationship
found
type
antiretrovir
regimen
infect
statu
certainti
evid
across
outcom
low
due
uncertainti
due
limit
sampl
size
lack
uniform
regimen
use
treat
patient
lack
inform
regard
intens
exposur
appendix
titl
screen
regist
trial
identifi
plan
assess
safeti
efficaci
antiretrovir
assess
lpvr
includ
treatment
mer
one
sar
rest
two
ritonavir
two
darunavir
cobicistat
one
tenofovir
alafenamid
fumar
estim
complet
date
march
januari
appendix
systemat
review
identifi
two
random
trial
observ
studi
provid
clinic
outcom
data
use
lpvr
treatment
sar
mer
random
trial
show
clinic
benefit
observ
studi
inconclus
certainti
bodi
evid
across
import
outcom
low
low
base
avail
evid
uncertain
whether
lpvr
antiretrovir
improv
clinic
outcom
sever
symptomat
diseas
prevent
infect
among
patient
high
risk
acquir
differ
potenti
therapeut
effect
lpvr
sar
mer
may
partli
due
differ
clinic
present
mani
patient
complic
cours
includ
stay
intens
care
unit
multipl
concurr
unproven
treatment
sever
random
trial
plan
assess
safeti
efficaci
antiretrovir
drug
includ
lpvr
treatment
conduct
trial
challeng
high
qualiti
evid
need
improv
clinic
programmat
decis
use
antiretrovir
drug
current
futur
coronaviru
outbreak
procur
use
lpvr
antiretrovir
drug
treat
prevent
infect
take
consider
need
ensur
continu
avail
peopl
live
hiv
need
lpvr
part
antiretrovir
therapi
overus
lpvr
current
epidem
run
risk
shortag
drug
current
use
second
line
treatment
peopl
live
hiv
plan
updat
review
least
monthli
throughout
longer
need
updat
evid
new
studi
complet
author
conflict
interest
declar
nf
sn
conceiv
review
nf
undertook
review
extract
data
verifi
ar
nf
ac
sn
ar
mv
md
interpret
data
author
contribut
write
manuscript
approv
final
version
author
alon
respons
view
express
articl
necessarili
repres
view
organ
